{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Tammen H"],"funding":["Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance"],"pubmed_abstract":["Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes, with additional beneficial effects for the kidney. Treatment of mice with linagliptin revealed increased storage of cobalamin (Cbl, Vitamin B12) in organs if a standard Cbl diet (30 µg Cbl/kg chow) is given. In order to translate these findings to humans, we determined methylmalonic acid (MMA), a surrogate marker of functional Cbl homeostasis, in human plasma and urine samples (n = 1092) from baseline and end of trial (6 months after baseline) of the previously completed MARLINA-T2D clinical trial. We found that individuals with medium Cbl levels (MMA between 50 and 270 nmol/L for plasma, 0.4 and 3.5 µmol/mmol creatinine for urine, at baseline and end of trial) exhibited higher MMA values a"],"journal":["Scientific reports"],"pagination":["601"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9837112"],"repository":["biostudies-literature"],"pubmed_title":["Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans."],"pmcid":["PMC9837112"],"pubmed_authors":["Tammen H","Klein T","von Eynatten M","Frankenreiter S","Komhoff M","Hocher B","Mark M","Delic D","Lund SS","Hess R"],"additional_accession":[]},"is_claimable":false,"name":"Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans.","description":"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes, with additional beneficial effects for the kidney. Treatment of mice with linagliptin revealed increased storage of cobalamin (Cbl, Vitamin B12) in organs if a standard Cbl diet (30 µg Cbl/kg chow) is given. In order to translate these findings to humans, we determined methylmalonic acid (MMA), a surrogate marker of functional Cbl homeostasis, in human plasma and urine samples (n = 1092) from baseline and end of trial (6 months after baseline) of the previously completed MARLINA-T2D clinical trial. We found that individuals with medium Cbl levels (MMA between 50 and 270 nmol/L for plasma, 0.4 and 3.5 µmol/mmol creatinine for urine, at baseline and end of trial) exhibited higher MMA values a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T20:32:55.021Z","creation":"2025-04-04T20:32:55.021Z"},"accession":"S-EPMC9837112","cross_references":{"pubmed":["36635409"],"doi":["10.1038/s41598-023-27648-7"]}}